Back to Search
Start Over
LocoMMotion
- Source :
- Leukemia, 36(5), 1371-1376. Nature Publishing Group, Mateos, M-V, Weisel, K, de Stefano, V, Goldschmidt, H, Delforge, M, Mohty, M, Cavo, M, Vij, R, Lindsey-Hill, J, Dytfeld, D, Angelucci, E, Perrot, A, Benjamin, R, van de Donk, N W C J, Ocio, E M, Scheid, C, Gay, F, Roeloffzen, W, Rodriguez-Otero, P, Broijl, A, Potamianou, A, Sakabedoyan, C, Semerjian, M, Keim, S, Strulev, V, Schecter, J M, Vogel, M, Wapenaar, R, Nesheiwat, T, San-Miguel, J, Sonneveld, P, Einsele, H & Moreau, P 2022, ' LocoMMotion : a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma ', Leukemia, vol. 36, no. 5, pp. 1371-1376 . https://doi.org/10.1038/s41375-022-01531-2
- Publication Year :
- 2022
-
Abstract
- Despite treatment advances, patients with multiple myeloma (MM) often progress through standard drug classes including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies (mAbs). LocoMMotion (ClinicalTrials.gov identifier: NCT04035226) is the first prospective study of real-life standard of care (SOC) in triple-class exposed (received at least a PI, IMiD, and anti-CD38 mAb) patients with relapsed/refractory MM (RRMM). Patients (N = 248; ECOG performance status of 0–1, ≥3 prior lines of therapy or double refractory to a PI and IMiD) were treated with median 4.0 (range, 1–20) cycles of SOC therapy. Overall response rate was 29.8% (95% CI: 24.2–36.0). Median progression-free survival (PFS) and median overall survival (OS) were 4.6 (95% CI: 3.9–5.6) and 12.4 months (95% CI: 10.3–NE). Treatment-emergent adverse events (TEAEs) were reported in 83.5% of patients (52.8% grade 3/4). Altogether, 107 deaths occurred, due to progressive disease (n = 74), TEAEs (n = 19), and other reasons (n = 14). The 92 varied regimens utilized demonstrate a lack of clear SOC for heavily pretreated, triple-class exposed patients with RRMM in real-world practice and result in poor outcomes. This supports a need for new treatments with novel mechanisms of action.
Details
- Language :
- English
- ISSN :
- 08876924
- Volume :
- 36
- Issue :
- 5
- Database :
- OpenAIRE
- Journal :
- Leukemia
- Accession number :
- edsair.doi.dedup.....d7529e558a5210ec8c0305a9ebc7f089